AMG - Pharm Spółka z Ograniczoną Odpowiedzialnością (KRS 0000573255, NIP 9231695805) is a Polish company, headquartered in Przemęt, Wielkopolskie voivodeship. AMG - PHARM operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since September 1, 2015. AMG - PHARM's most recently reported net revenue was 0 PLN for 2023.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - AMG - Pharm
Identity
- Name
- AMG - Pharm Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- September 1, 2015
- Registry status as of
- May 10, 2026
- Latest entry
- May 10, 2026
- Founding act
- 12.08.2015R., NOTARIUSZ JANINA KATYŃSKA-URBAN, KANCELARIA NOTARIALNA W WOLSZTYNIE, REP. A NR 4609/2015
Articles of association history (2)
- August 12, 2015: 12.08.2015R., NOTARIUSZ JANINA KATYŃSKA-URBAN, KANCELARIA NOTARIALNA W WOLSZTYNIE, REP. A NR 4609/2015
- October 6, 2022: 06.10.2022 R., NOTARIUSZ BARTŁOMIEJ JANICKI, KANCELARIA NOTARIALNA W ALEKSANDROWIE ŁÓDZKIM, REP. A NR 6233/2022 - ZMIENIONO TREŚĆ UMOWY SPÓŁKI W FORMIE PRZYJĘCIA NOWEGO TEKSTU JEDNOLITEGO
Activities
Main activity
47.73.ZDispensing chemist in specialised stores
Other activities
Address and contact
- Address
- UL. JAGIELLOŃSKA, 22A, 64-234, PRZEMĘT, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- WOLSZTYŃSKI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-20500-44858-HRUVB-32
Risk and payment profile - AMG - Pharm
Credibility rating
48.9 / 100
Average credibility
Insolvency risk
Very low
Elevated threat
Closure risk
25
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/11 yrs
Board changes
3
3/11 yrs
PKD changes
1
1/11 yrs
Name changes
0
0/11 yrs
Data from 11 years of registry activity.
Credibility history
Payment reliability score from 2021–2023
Current: D (49/100)
Trend: deteriorating (-11.7 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2021–2023
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - AMG - Pharm
Founded
September 1, 2015
10 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
PRZEMĘT
WIELKOPOLSKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
5.0 K PLN
50 shares total
Shareholders
2
shareholders
Board
3 people
Filed years
3 years
2021–2023 · profitable: 2/3
Registry entries
31
latest: May 10, 2026
Risk signals
Revenue
0 PLN
2023
Net profit
-1.1 K PLN
2023
Assets
103.5 K PLN
2023
Equity
101.7 K PLN
2023
EBITDA
N/A
2023
no depreciation data
Valuation
77.2 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - AMG - Pharm.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
